Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Common Equity (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Common Equity for 16 consecutive years, with $14.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 78.46% to $14.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.1 million, a 78.46% decrease, with the full-year FY2024 number at $63.3 million, down 13.32% from a year prior.
  • Common Equity was $14.1 million for Q3 2025 at Harvard Bioscience, down from $15.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $83.4 million in Q4 2021 to a low of $14.1 million in Q3 2025.
  • A 5-year average of $64.2 million and a median of $73.1 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: grew 8.76% in 2021, then plummeted 78.46% in 2025.
  • Harvard Bioscience's Common Equity stood at $83.4 million in 2021, then dropped by 13.41% to $72.2 million in 2022, then rose by 1.18% to $73.1 million in 2023, then dropped by 13.32% to $63.3 million in 2024, then tumbled by 77.79% to $14.1 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Common Equity are $14.1 million (Q3 2025), $15.7 million (Q2 2025), and $14.8 million (Q1 2025).